The Effect of Avidin on Viability and Proliferation of Colorectal Cancer Cells HT-29

Document Type : Research Articles


1 Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia, Indonesia.

2 Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Indonesia.

3 Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia.


Objective: The aim of this study was to analyze the effect of avidin treatment on cell viability, proliferation and cyclin D1 expression in colorectal cancer cells HT-29. Methods: Colorectal cancer cell line HT-29 incubated with 50, 100, 150, and 200 μg/mL of avidin concentration during 24, 48, and 72 hours, then the cell viability and proliferation   were analyzed. Each avidin concentration was conducted together with HT-29 cell line without avidin treatment as a control group. The cell viability was measured by MTS assay and the proliferation was measured by BrdU (5-bromo-2′-deoxyuridine) cell proliferation assay. According to cell viability and proliferation result, we determined the 100 μg/mL avidin concentration for analyzing mRNA and protein of cyclin D1. Results: We demonstrated that the viability and proliferation of HT-29 cells were significantly decreased in all concentration of avidin treatment compared to control.   The cell proliferation showed larger reduction in avidin treatment rather than cell viability. This proves avidin could inhibit proliferation of colorectal cancer cell HT-29 quite well. The expression of cyclin D1, both mRNA and protein, was also significantly decreased after the avidin treatment group compared to control group, it supports the suppression of proliferation result. Conclusion: We concluded that avidin treatment could decrease cell viability and proliferation, accompanied by suppression of cyclin D1 expression in colorectal cells HT-29. 


Main Subjects

Volume 23, Issue 6
June 2022
Pages 1967-1973
  • Receive Date: 02 January 2022
  • Revise Date: 20 April 2022
  • Accept Date: 17 June 2022
  • First Publish Date: 17 June 2022